机械设备：意念赋能新生活，脑机接口启新篇

Investment Rating - The industry rating is "Outperform the Market" [8] Core Insights - The first Neuralink brain-computer interface (BCI) implant recipient, Nolan Abbot, has regained significant abilities, such as typing and playing games using thoughts, and is pursuing a degree in neuroscience [3] - Abbot's device, named "Eve," has shown promising results, with plans for a major announcement in early 2026, marking two years since the implant [5] - The BCI market is projected to grow rapidly, with a global market size expected to reach approximately $2.62 billion in 2024, $2.94 billion in 2025, and $12.4 billion by 2034, reflecting a compound annual growth rate (CAGR) of 17.35% over ten years [6] Summary by Sections - Market Growth Potential: The BCI market is anticipated to expand significantly, with China's market expected to grow from 3.2 billion yuan in 2024 to 6.14 billion yuan by 2028, supported by national strategic initiatives [6] - Clinical Trials and Applications: As more individuals participate in clinical trials, Neuralink's technology is expected to continue to evolve, aiding patients in regaining normalcy and showcasing broad potential across various applications [5] - Investment Opportunities: Companies to watch include Yanshan Technology, Hanwei Technology, Sanbo Brain Science, Innovation Medical, Dongfang Zhongke, Xiangyu Medical, Entropy Technology, Chengyitong, Weisi Medical, Mcland, Aipeng Medical, and Beiyikang [7]